Abstract
Emerging infectious diseases are increasingly understood as a hallmark of the Anthropocene1–3. Most experts agree that anthropogenic ecosystem change and high-risk contact among people, livestock, and wildlife have contributed to the recent emergence of new zoonotic, vector-borne, and environmentally-transmitted pathogens1,4–6. However, the extent to which these factors also structure landscapes of human infection and outbreak risk is not well understood, beyond certain well-studied disease systems7–9. Here, we consolidate 58,319 unique records of outbreak events for 32 emerging infectious diseases worldwide, and systematically test the influence of 16 hypothesized social and environmental drivers on the geography of outbreak risk, while adjusting for multiple detection, reporting, and research biases. Across diseases, outbreak risks are widely associated with mosaic landscapes where people live alongside forests and fragmented ecosystems, and are commonly exacerbated by long-term decreases in precipitation. The combined effects of these drivers are particularly strong for vector-borne diseases (e.g., Lyme disease and dengue fever), underscoring that policy strategies to manage these emerging risks will need to address land use and climate change10–12. In contrast, we find little evidence that spillovers of directly-transmitted zoonotic diseases (e.g., Ebola virus disease and mpox) are consistently associated with these factors, or with other anthropogenic drivers such as deforestation and agricultural intensification13. Most importantly, we find that observed spatial outbreak intensity is primarily an artefact of the geography of healthcare access, indicating that existing disease surveillance systems remain insufficient for comprehensive monitoring and response: across diseases, outbreak reporting declined by a median of 32% (range 1.2%-96.7%) for each additional hour’s travel time from the nearest health facility. Our findings underscore that disease emergence is a multicausal feature of social-ecological systems, and that no one-size-fits-all global strategy can prevent epidemics and pandemics. Instead, ecosystem-based interventions should follow regional priorities and system-specific evidence, and be paired with investment in One Health surveillance and health system strengthening.
Competing Interest Statement
Related research funding: BVS, CJC, DWR, KEJ, and RG have received research grants from the Coalition for Epidemic Preparedness Innovations. Consulting: BH has been a consultant to the Wellcome Trust on emerging infectious diseases. CJC has been a consultant for the US Department of State on Global Health issues. Government advisory roles: RK is a senior advisor at the U.S. Department of State Bureau of Global Health Security and Diplomacy. Non-governmental advisory roles: DJB is a current member of the Lancet-PPATS Commission on Prevention of Viral Spillover. CJC, CHT, and SJR have been contributing authors on related reports by the Intergovernmental Panel on Climate Change. CJC has been a contributing author on related reports by the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services. HC-E has been a contributor to related reports by the International Union for the Conservation of Nature. RK is a current member of the Pandemic Fund Technical Advisory Panel.
Funding Statement
This work was supported by an NSF Biology Integration Institute grant (NSF DBI 2021909 and 2213854), which supported RG, SJR, RM, GFA, DJB, EAE, HKF, BAH, SNS, and CJC, as well as the Verena Institute collaborative platform under which this work was organized (viralemergence.org). Further support came from the Trinity Challenge (RG, KEJ, DWR), the Wolfson Foundation (via a UCL Excellence Fellowship; RG), the Bill and Melinda Gates foundation (grant OPP#1181128; DMP), Bryce Carmine and Anne Carmine (nee Percival) through the Massey University Foundation (RLM), the Wellcome Trust (award no. 101103/Z/13/Z; DL), and Schmidt Sciences (CHT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code, data (where not subject to sharing constraints) and disease-specific results objects (e.g. CSVs of parameter estimates; rasters of fitted geospatial effects) are available on GitHub at github.com/viralemergence/fingerprint-preprint.
